While the manuscript of our study was being reviewed, a press release regarding the KEYNOTE-355 trial announced that pembrolizumab plus chemotherapy significantly improved progression-free survival compared to chemotherapy alone in patients with metastatic TNBC whose tumor expressed PD-L1 with a Combined Positive Score of ≥ 10 (https://bit.ly/2HtT4rj; unpublished data). The gene discussed is CD274; the disease is neoplasm.